咪唑烷三酮,[(3-硝基苯基)甲基]- | 105686-03-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 咪唑烷三酮,[(3-硝基苯基)甲基]-
• 英文名称: 1-(3-nitrobenzyl)imidazolidine-2,4,5-trione
• 英文别名: 1-(3-nitrobenzyl)imidazolidinetrione；1-[(3-Nitrophenyl)methyl]imidazolidine-2,4,5-trione
• CAS: 105686-03-1
• 化学式: C₁₀H₇N₃O₅
• 分子量: 249.183
• InChiKey: RDOKLEZVZCADLN-UHFFFAOYSA-N

物化性质

• 密度：
  1.602±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  112
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  咪唑烷三酮,[(3-硝基苯基)甲基]- 在 盐酸 、 氢氧化钾 、 溶剂黄146 作用下， 以 乙醇 为溶剂， 反应 12.5h， 生成 3-(3-nitrobenzyl)-2,4,5-trioxoimidazolidine-1-acetic acid
  参考文献：
  名称：

  Highly Selective Aldose Reductase Inhibitors. 1. 3-(Arylalkyl)-2,4,5-trioxoimidazolidine-1-acetic Acids

  摘要：

  A series of 3-(arylalkyl)-2,4,5-trioxoimidazolidine-1-acids (1) was prepared and tested for aldose reductase (AR) and aldehyde reductase (ALR) inhibitory activities. These compounds showed strong inhibitory activity against AR without significant inhibitory activity for ALR. The ratio of IC50(ALR)/IC50(AR) was > 1000 in some compouds. On the basis of pharmacological tests such as the recovery of reduced motor nerve conduction velocity and toxicological profile, 3-(3-nitrobenzyl)-2,4,5-trioxoimidazolidine-1-acid (NZ-314) was selected as the candidate for clinical development.

  DOI：

  10.1021/jm9508393
• 作为产物：
  描述：

  3-硝基苄胺盐酸盐 在 盐酸 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 6.0h， 生成 咪唑烷三酮,[(3-硝基苯基)甲基]-
  参考文献：
  名称：

  Highly Selective Aldose Reductase Inhibitors. 1. 3-(Arylalkyl)-2,4,5-trioxoimidazolidine-1-acetic Acids

  摘要：

  A series of 3-(arylalkyl)-2,4,5-trioxoimidazolidine-1-acids (1) was prepared and tested for aldose reductase (AR) and aldehyde reductase (ALR) inhibitory activities. These compounds showed strong inhibitory activity against AR without significant inhibitory activity for ALR. The ratio of IC50(ALR)/IC50(AR) was > 1000 in some compouds. On the basis of pharmacological tests such as the recovery of reduced motor nerve conduction velocity and toxicological profile, 3-(3-nitrobenzyl)-2,4,5-trioxoimidazolidine-1-acid (NZ-314) was selected as the candidate for clinical development.

  DOI：

  10.1021/jm9508393

文献信息

• Parabanic acid derivatives and pharmaceutical compositions thereof
  申请人：Nippon Zoki Pharmaceutical Co., Ltd.

  公开号：US04985453A1

  公开（公告）日：1991-01-15

  Parabanic acid compound of the formula (I): ##STR1## wherein R is hydrogen or a lower alkyl group, X is hydrogen, an alkyl group, a cycloalkyl group, a lower alkylcycloalkyl group, a phenyl group or a phenalkyl group, and n represents an integer of 1 to 4, exhibit excellent aldose reductase inhibitory activity and are useful as drugs for treating or prevention of complications of diabetes.

  化合物Parabanic acid的化学式为(I): ##STR1## 其中R为氢或低碳基，X为氢，烷基，环烷基，低碳基环烷基，苯基或苯基烷基，n表示1至4的整数，具有出色的醛糖还原酶抑制活性，可用作治疗或预防糖尿病并发症的药物。
• A pharmaceutical composition containing an imidazolidinetrione derivative or pharmaceutically acceptable salt thereof
  申请人：NIPPON ZOKI PHARMACEUTICAL CO. LTD.

  公开号：EP0194226A1

  公开（公告）日：1986-09-10

  Pharmaceutical compositions contain as an active ingredient oxaluric acid derivatives of the formula (I): wherein each of R, and R2, which may be the same or different, represents hydrogen or an alkyl or cycloalkyl group or the group and each of R3 and R4, which may be the same or different, represents hydrogen, halogen, a nitro group or a lower alkyl or lower alkoxy group, and pharmaceutically acceptable salts and metal complexes thereof. The compositions have hypoglycemic and hypolipidemic acitivity. Several of the compounds disclosed are novel per se.

  药物组合物含有式（I）的草酸衍生物作为活性成分： 其中 R 和 R2（可以相同或不同）各自代表氢或烷基或环烷基或基团 以及 R3 和 R4（可以相同或不同）各自代表氢、卤素、硝基或低级烷基或低级烷氧基，以及它们的药学上可接受的盐和金属络合物。这些组合物具有降血糖和降血脂活性。所公开的化合物中有几种本身就是新颖的。
• US4683240A
  申请人：——

  公开号：US4683240A

  公开（公告）日：1987-07-28